Organogenesis Holdings Inc ORGO.OQ ORGO.O is expected to show a rise in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
The Canton Massachusetts-based company is expected to report a 16.4% increase in revenue to $134.1 million from $115.18 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on August 7 2025, for the period ended September 30, was for revenue between $130.00 million and $145.00 million.
LSEG's mean analyst estimate for Organogenesis Holdings Inc is for earnings of 6 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Organogenesis Holdings Inc is $8.00, about 50% above its last closing price of $4.00
The company's guidance on August 7 2025 for the period ended September 30 was for gross profit margin between USD74% and USD76%.
This summary was machine generated November 4 at 21:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments